{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:06:31Z","timestamp":1789056391170,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201803","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:27:05Z","timestamp":1783121225000},"page":"201803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic and pharmacodynamic characterization of CD8-targeted lentiviral vector for in vivo CD19-directed CAR-T therapy"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-179X","authenticated-orcid":false,"given":"Victoria","family":"Duback","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalu S.","family":"Kharkwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasily","family":"Vagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrie","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Sabbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amey","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Dolinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelan","family":"Hlavaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Zipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Koppes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindu","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Trudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagesh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3085-096X","authenticated-orcid":false,"given":"Kutlu G.","family":"Elpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201803_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201803_bib2","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.3390\/ijms24076300","article-title":"CAR T Cell Therapy: A Versatile Living Drug","volume":"24","author":"De Marco","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2026.201803_bib3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.omta.2026.201803_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5474602","article-title":"CAR T Cell Therapy: A Game Changer in Cancer Treatment","volume":"2016","author":"Alm\u00e5sbak","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.omta.2026.201803_bib5","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201803_bib6","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omta.2026.201803_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omta.2026.201803_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-024-01568-z","article-title":"Advances in CAR-T-cell therapy in T-cell malignancies","volume":"17","author":"Zheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omta.2026.201803_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-cancerbio-062822-023316","article-title":"Allogeneic CAR T Cell Therapy for Cancer","volume":"8","author":"Sasu","year":"2024","journal-title":"Ann. Rev. Cancer Biol."},{"key":"10.1016\/j.omta.2026.201803_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omta.2026.201803_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.809754","article-title":"In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omta.2026.201803_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12935-021-01763-9","article-title":"Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer","volume":"21","author":"Jin","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.omta.2026.201803_bib13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omta.2026.201803_bib14","first-page":"1823","article-title":"Optimizing In Vivo CAR-T Cell Engineering for Cancer Immunotherapy","volume":"86","author":"Wang","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.omta.2026.201803_bib15","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/v15030698","article-title":"Viral Vectors in Gene Therapy: Where Do We Stand in 2023?","volume":"15","author":"Lundstrom","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.omta.2026.201803_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omta.2026.201803_bib17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12951-023-02044-5","article-title":"Emerging non-viral vectors for gene delivery","volume":"21","author":"Wang","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.omta.2026.201803_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307796121","article-title":"Targeted nonviral delivery of genome editors in vivo","volume":"121","author":"Tsuchida","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201803_bib19","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201803_bib20","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.1128\/JVI.03298-12","article-title":"The Receptor Attachment Function of Measles Virus Hemagglutinin Can Be Replaced with an Autonomous Protein That Binds Her2\/neu While Maintaining Its Fusion-Helper Function","volume":"87","author":"Rasbach","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201803_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005641","article-title":"Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment","volume":"12","author":"Bender","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omta.2026.201803_bib22","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1093\/infdis\/jiad123","article-title":"Paramyxoviruses: Pathogenesis, Vaccines, Antivirals, and Prototypes for Pandemic Preparedness","volume":"228","author":"Duprex","year":"2023","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.omta.2026.201803_bib23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in non-human primates using lentiviral vectors displaying a multi-domain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201803_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omta.2026.201803_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1671761","article-title":"In vivo generated human CAR T cells eradicate tumor cells","volume":"8","author":"Agarwal","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.omta.2026.201803_bib26","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201803_bib27","first-page":"5702","article-title":"Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors","volume":"4","author":"Frank","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201803_bib28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/d41573-024-00150-z","article-title":"In vivo CAR T cells move into clinical trials","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omta.2026.201803_bib29","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","article-title":"In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study","volume":"32","author":"An","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201803_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201803_bib31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.omtm.2022.12.013","article-title":"Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication","volume":"28","author":"Dambra","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201803_bib32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-023-00842-1","article-title":"PK\/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position Paper","volume":"25","author":"Kavita","year":"2023","journal-title":"AAPS J."},{"key":"10.1016\/j.omta.2026.201803_bib33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41551-023-01013-5","article-title":"A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor","volume":"7","author":"Reichenbach","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omta.2026.201803_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-024-03179-5","article-title":"In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma","volume":"43","author":"Krug","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omta.2026.201803_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.xphs.2023.10.005","article-title":"Whole-Body Disposition and Physiologically Based Pharmacokinetic Modeling of Adeno-Associated Viruses and the Transgene Product","volume":"113","author":"Liu","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.omta.2026.201803_bib36","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1016\/j.jtha.2024.07.012","article-title":"Adeno-associated viral vector integration: implications for long-term efficacy and safety","volume":"22","author":"Batty","year":"2024","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.omta.2026.201803_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097639","article-title":"Recombinant adeno-associated virus: Efficient transduction of the rat VMH and clearance from blood","volume":"9","author":"Van Gestel","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201803_bib38","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12967-025-07626-5","article-title":"Adaptation of lentiviral vectors for viral gene therapy and their impact on host cell biology","volume":"24","author":"Kaiser","year":"2026","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omta.2026.201803_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.omta.2025.201660","article-title":"Normothermic perfusion of human livers for profiling lentiviral vector pharmacokinetics and transduction","volume":"34","author":"Nicholls","year":"2026","journal-title":"Mol. Ther. Adv."},{"key":"10.1016\/j.omta.2026.201803_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/mthe.2002.0630","article-title":"Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow","volume":"6","author":"Pan","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201803_bib41","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.gt.3301552","article-title":"Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors","volume":"8","author":"Peng","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201803_bib42","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","article-title":"Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation","volume":"33","author":"Andorko","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201803_bib43","first-page":"361","article-title":"Assessment of Hazard Risk Associated with the Intravenous Use of Viral Vectors in Rodents","volume":"62","author":"Reuter","year":"2012","journal-title":"Comp. Med."},{"key":"10.1016\/j.omta.2026.201803_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-136459","article-title":"Vector Shedding and Blood Biodistribution in Patients with Severe Hemophilia a Following Administration of Valoctocogene Roxaparvovec","volume":"136","author":"Clark","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201803_bib45","unstructured":"Youngman E.M., Kuri-Cervantes L., Edwards S., Miranda M., Schreiber C., Richardson J., Culp T., Johnson P.R..(2024) Pharmacokinetics and Vector Shedding in NHPs Following a Single Intravenous Infusion of a CD20-Targeted Engineered Lentiviral Vector, MOLECULAR THERAPY, 32, 126, Proceedings of the 27th Annual Meeting of the American Society of Gene & Cell Therapy; Baltimore, MD, USA. 7\u201311 May."},{"key":"10.1016\/j.omta.2026.201803_bib46","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.21873\/anticanres.14540","article-title":"The development of next-generation PBMC humanized mice for preclinical investigation of cancer immunotherapeutic agents","volume":"40","author":"Morillon","year":"2020","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omta.2026.201803_bib47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/acsptsci.0c00178","article-title":"Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development","volume":"4","author":"Ma","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.omta.2026.201803_bib48","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.xphs.2020.12.015","article-title":"Addressing Patient to Patient Variability for Autologous CAR T Therapies","volume":"110","author":"Jiang","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.omta.2026.201803_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf0567","article-title":"Inflammatory CD4\/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology","volume":"9","author":"Hess","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omta.2026.201803_bib50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtm.2022.08.008","article-title":"Applying a clinical lens to animal models of CAR-T cell therapies","volume":"27","author":"Duncan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201803_bib51","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41590-024-01880-3","article-title":"A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses","volume":"25","author":"Chupp","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omta.2026.201803_bib52","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-07934-1","article-title":"Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies","volume":"21","author":"Ying","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omta.2026.201803_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94490-0","article-title":"Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model","volume":"11","author":"Sta Maria","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201803_bib54","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1182\/blood-2023-190158","article-title":"In Vitro and In Vivo Specificity and Biodistribution of a Novel CD8-Targeted Fusosome","volume":"142","author":"Chavan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201803_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav7325","article-title":"Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates","volume":"11","author":"Milani","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201803_bib56","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/cmi.2017.106","article-title":"Human PBMC-transferred murine MHC class I\/II-deficient NOG mice enable long-term evaluation of human immune responses","volume":"15","author":"Yaguchi","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omta.2026.201803_bib57","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtm.2022.06.004","article-title":"In vivo generation of CAR T cells in the presence of human myeloid cells","volume":"26","author":"Ho","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201803_bib58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/CJI.0b013e3182187600","article-title":"Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies","volume":"34","author":"Kerkar","year":"2011","journal-title":"J. Immunother."},{"key":"10.1016\/j.omta.2026.201803_bib59","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.vetimm.2011.06.002","article-title":"Retroviral restriction and dependency factors in primates and carnivores","volume":"143","author":"Fadel","year":"2011","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.omta.2026.201803_bib60","doi-asserted-by":"crossref","first-page":"40875","DOI":"10.1074\/jbc.R112.416925","article-title":"The restriction factors of human immunodeficiency virus","volume":"287","author":"Harris","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201803_bib61","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/cells12050732","article-title":"Host Cell Restriction Factors Blocking Efficient Vector Transduction: Challenges in Lentiviral and Adeno-Associated Vector Based Gene Therapies","volume":"12","author":"Coroadinha","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.omta.2026.201803_bib62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:11:37Z","timestamp":1789053097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001382"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201803","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and pharmacodynamic characterization of CD8-targeted lentiviral vector for in vivo CD19-directed CAR-T therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201803"}}